Accessing sustainable pipeline growth through N1 delivery platform
Transforming Previous R&D Loss into Gold Mine for Drug Development
About N1 Life
N1 Life, Inc. is a biopharma company founded at Stanford in 2019. The company focuses on the early development (preclinical to early clinical) of new therapeutics using its barrier-penetrating delivery platform. The N1 delivery technology enables a fast-path strategy to the clinic and consumer market by maximizing the benefit of known drugs/drug candidates and existing data, and accessing the previously undruggable space.
N1 Life is creating an innovative and sustainable model consisting of therapeutic pipeline, screening service, and consumer product program.
N1 Delivery Platform
N1 Life develops new therapeutic candidates by learning from preclinical and clinical data of existing drugs or drug candidates, and maximizing their advantages through the innovative N1 delivery technology.
Rethink drug development
Rescue drug failures
Reinvestigate existing data
Recover sunk R&D cost
The Core of Innovation
Lin Cheng, PhD
VP of Chemistry
20 years industry experience in new drug discovery, drug delivery, polymer-drug conjugation, medicinal chemistry and polymer chemistry. Involved in programs that generated novel compounds from preclinical candidates to FDA approved drugs in therapeutic areas including immuno-oncology, inflammation, pain, HIV and renal diseases. Inventor of Movantik, an FDA approved oral peripherally acting mu-opioid receptor antagonist (PAMORA) medicine.
Legal Counsel & Operation Advisor
CA & NY Bar.
Held various executive positions (business and legal) at a startup that raised over $21M from a top tier VC and won global awards for its product. W as a senior attorney at Orrick, Herrington & Sutcliffe LLP, working with investments in then pre-IPO startup companies like Financial Engines (NASDAQ: FNGN), Trulia (NYSE: TRLA) and LinkedIn (NYSE: LNKD).